Managing dyslipidemia in the high-risk patient

American Journal of Cardiology

Volumn 89, Issue 5 SUPPL. 1, 2002, Pages 50-57

  Stein, Evan A ^a,b  

^a Pharmaceutical Product Development   (United States)

^b Metab and Atherosclerosis Res Ctr   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DIMETHOXYPHENYL) 3 (3 ETHYLVALERYL) 4 HYDROXY 6,7,8 TRIMETHOXY 2 NAPHTHOIC ACID METHYL ESTER; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STANOL ESTER; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GOUT; HEART PROTECTION; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; LIPID ABSORPTION; MEDICAL SOCIETY; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN IRRITATION; TREATMENT INDICATION;

EID: 0037034970     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02229-4     Document Type: Conference Paper

References (40)

1. The lipid research clinics coronary primary prevention trial results
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. The effect of pravastatin on cholesterol events
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
7. Statins: Effective antiatherosclerotic therapy
8. Maximizing the cost-effectiveness of lipid-lowering therapy
9. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
10. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
11. Management of dyslipidemia in adults with diabetes
12. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
13. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein goals
14. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro heart survey programme
15. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
16. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins
17. Drug treatment of lipid disorders
18. Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects
19. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing
20. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
21. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated
22. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association
23. Compliance with and efficacy of treatment with pravastatin and cholestyramine: A randomized study on lipid-lowering in primary care
24. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively
25. Treatment of hyperlipidemia with combined niacin-statin regimens
26. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy
27. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
28. Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia
29. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
30. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia
31. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin vs atorvastatin in patients with type IIa or IIb hypercholesterolemia
32. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemic patients: A randomised, double-blind study
33. Effect of rosuvastatin on high density lipoprotein cholesterol and apolipoprotein AI in patients with heterozygous familial hypercholesterolemia
34. Intestinal bile salt transport: Structure-activity relationships and other properties
35. Inhibition of ileal sodium-dependent bile acid transport by 2164U90
36. +/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits
37. Intestinal bile acid transporter (IBAT) inhibition: Results of a 4 week pilot study of 264W94*, a novel IBAT inhibitor in hypercholesterolemia
38. Low-density-lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesteremic subjects: Results of a dose-response study. Presented at XIIth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-20, 2000
39. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
40. Multiple contributors to coronary risk implications for screening and prevention